Photo by profwicks from unsplash
We read with interest the meta-analysis performed by Djulbegovic et al about the use of caplacizumab as a treatment for patients with immune thrombotic thrombocytopenic purpura (iTTP). 1 We respectfully… Click to show full abstract
We read with interest the meta-analysis performed by Djulbegovic et al about the use of caplacizumab as a treatment for patients with immune thrombotic thrombocytopenic purpura (iTTP). 1 We respectfully disagree with some of the conclusions drawn by the authors. Firstly, the authors state that the addition of caplacizumab to the standard of care did not signi fi cantly reduce all-cause mortality compared with standard of care alone
Keywords:
addition;
ittp;
caplacizumab frontline;
standard;
caplacizumab;
treatment
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!